Shares in NeuroMetrix (NSDQ:NURO) soared this morning after the company announced it would partner with GlaxoSmithKline (NYSE:GSK) to expand development of NeuroMetrix’s Quell wearable pain-relief device.
According to the terms of the deal, GSK’s consumer healthcare business will have exclusive rights to the Quell system for markets outside of the U.S., while NeuroMetrix will retain ownership of the device within the U.S.
Get the full story at our sister site, Drug Delivery Business News.
The post NeuroMetrix, GSK ink development deal for Quell wearable pain-relief tech appeared first on MassDevice.
from MassDevice http://ift.tt/2DG4PIh
Cap comentari:
Publica un comentari a l'entrada